vs
SERVICE CORP INTERNATIONAL（SCI）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
SERVICE CORP INTERNATIONALの直近四半期売上が大きい（$1.1B vs $790.2M、UNITED THERAPEUTICS Corpの約1.4倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 14.3%、差は31.8%）。UNITED THERAPEUTICS Corpの前年同期比売上増加率が高い（7.4% vs 1.7%）。UNITED THERAPEUTICS Corpの直近四半期フリーキャッシュフローが多い（$173.3M vs $87.2M）。過去8四半期でUNITED THERAPEUTICS Corpの売上複合成長率が高い（8.0% vs 3.1%）
国際流通サービス有限会社（IDS）は英国の郵便・宅配便サービス事業者です。2013年に英国政府がロイヤルメールの持株会社として設立し、過半数の株式がロンドン証券取引所で売却され、当時政府は30%の株式を保有していました。2025年4月現在、ダニエル・クレティンスキー所有のチェコEPグループが同社を保有・運営しています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
SCI vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.1B | $790.2M |
| 純利益 | $159.4M | $364.3M |
| 粗利率 | 28.0% | 86.9% |
| 営業利益率 | 24.8% | 45.1% |
| 純利益率 | 14.3% | 46.1% |
| 売上前年比 | 1.7% | 7.4% |
| 純利益前年比 | 5.3% | 20.9% |
| EPS（希薄化後） | $1.13 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.1B | $790.2M | ||
| Q3 25 | $1.1B | $799.5M | ||
| Q2 25 | $1.1B | $798.6M | ||
| Q1 25 | $1.1B | $794.4M | ||
| Q4 24 | $1.1B | $735.9M | ||
| Q3 24 | $1.0B | $748.9M | ||
| Q2 24 | $1.0B | $714.9M | ||
| Q1 24 | $1.0B | $677.7M |
| Q4 25 | $159.4M | $364.3M | ||
| Q3 25 | $117.5M | $338.7M | ||
| Q2 25 | $122.9M | $309.5M | ||
| Q1 25 | $142.9M | $322.2M | ||
| Q4 24 | $151.4M | $301.3M | ||
| Q3 24 | $117.8M | $309.1M | ||
| Q2 24 | $118.2M | $278.1M | ||
| Q1 24 | $131.3M | $306.6M |
| Q4 25 | 28.0% | 86.9% | ||
| Q3 25 | 25.1% | 87.4% | ||
| Q2 25 | 25.5% | 89.0% | ||
| Q1 25 | 27.1% | 88.4% | ||
| Q4 24 | 28.0% | 89.7% | ||
| Q3 24 | 24.9% | 88.9% | ||
| Q2 24 | 24.9% | 89.1% | ||
| Q1 24 | 26.2% | 89.2% |
| Q4 25 | 24.8% | 45.1% | ||
| Q3 25 | 21.4% | 48.6% | ||
| Q2 25 | 21.1% | 45.6% | ||
| Q1 25 | 23.4% | 48.2% | ||
| Q4 24 | 24.0% | 48.6% | ||
| Q3 24 | 20.9% | 45.8% | ||
| Q2 24 | 21.4% | 44.7% | ||
| Q1 24 | 22.2% | 52.6% |
| Q4 25 | 14.3% | 46.1% | ||
| Q3 25 | 11.1% | 42.4% | ||
| Q2 25 | 11.5% | 38.8% | ||
| Q1 25 | 13.3% | 40.6% | ||
| Q4 24 | 13.8% | 40.9% | ||
| Q3 24 | 11.6% | 41.3% | ||
| Q2 24 | 11.4% | 38.9% | ||
| Q1 24 | 12.6% | 45.2% |
| Q4 25 | $1.13 | $7.66 | ||
| Q3 25 | $0.83 | $7.16 | ||
| Q2 25 | $0.86 | $6.41 | ||
| Q1 25 | $0.98 | $6.63 | ||
| Q4 24 | $1.02 | $6.23 | ||
| Q3 24 | $0.81 | $6.39 | ||
| Q2 24 | $0.81 | $5.85 | ||
| Q1 24 | $0.89 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $243.6M | $2.9B |
| 総負債低いほど良い | $5.1B | — |
| 株主資本純資産 | $1.6B | $7.1B |
| 総資産 | $18.7B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 3.10× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $243.6M | $2.9B | ||
| Q3 25 | $241.3M | $2.8B | ||
| Q2 25 | $255.4M | $3.0B | ||
| Q1 25 | $227.2M | $3.3B | ||
| Q4 24 | $218.8M | $3.3B | ||
| Q3 24 | $185.4M | $3.3B | ||
| Q2 24 | $184.4M | $3.0B | ||
| Q1 24 | $205.6M | $2.7B |
| Q4 25 | $5.1B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.7B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.7B | — | ||
| Q2 24 | $4.7B | — | ||
| Q1 24 | $4.6B | — |
| Q4 25 | $1.6B | $7.1B | ||
| Q3 25 | $1.6B | $6.6B | ||
| Q2 25 | $1.6B | $7.2B | ||
| Q1 25 | $1.7B | $6.8B | ||
| Q4 24 | $1.7B | $6.4B | ||
| Q3 24 | $1.6B | $6.1B | ||
| Q2 24 | $1.5B | $5.7B | ||
| Q1 24 | $1.6B | $5.3B |
| Q4 25 | $18.7B | $7.9B | ||
| Q3 25 | $18.4B | $7.4B | ||
| Q2 25 | $18.0B | $7.9B | ||
| Q1 25 | $17.3B | $7.7B | ||
| Q4 24 | $17.4B | $7.4B | ||
| Q3 24 | $17.4B | $7.1B | ||
| Q2 24 | $16.8B | $6.7B | ||
| Q1 24 | $16.7B | $6.5B |
| Q4 25 | 3.10× | — | ||
| Q3 25 | 3.17× | — | ||
| Q2 25 | 3.19× | — | ||
| Q1 25 | 2.87× | — | ||
| Q4 24 | 2.83× | — | ||
| Q3 24 | 2.92× | — | ||
| Q2 24 | 3.05× | — | ||
| Q1 24 | 2.90× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $212.9M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $87.2M | $173.3M |
| FCFマージンFCF / 売上 | 7.8% | 21.9% |
| 設備投資強度設備投資 / 売上 | 11.3% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 1.34× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $554.2M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $212.9M | $346.2M | ||
| Q3 25 | $252.3M | $562.1M | ||
| Q2 25 | $166.4M | $191.7M | ||
| Q1 25 | $311.1M | $461.2M | ||
| Q4 24 | $264.1M | $341.2M | ||
| Q3 24 | $263.8M | $377.2M | ||
| Q2 24 | $196.9M | $232.2M | ||
| Q1 24 | $220.1M | $376.5M |
| Q4 25 | $87.2M | $173.3M | ||
| Q3 25 | $150.7M | $351.6M | ||
| Q2 25 | $83.4M | $129.5M | ||
| Q1 25 | $233.0M | $386.3M | ||
| Q4 24 | $151.8M | $254.5M | ||
| Q3 24 | $162.8M | $300.7M | ||
| Q2 24 | $100.8M | $187.1M | ||
| Q1 24 | $140.3M | $338.3M |
| Q4 25 | 7.8% | 21.9% | ||
| Q3 25 | 14.2% | 44.0% | ||
| Q2 25 | 7.8% | 16.2% | ||
| Q1 25 | 21.7% | 48.6% | ||
| Q4 24 | 13.9% | 34.6% | ||
| Q3 24 | 16.1% | 40.2% | ||
| Q2 24 | 9.7% | 26.2% | ||
| Q1 24 | 13.4% | 49.9% |
| Q4 25 | 11.3% | 21.9% | ||
| Q3 25 | 9.6% | 26.3% | ||
| Q2 25 | 7.8% | 7.8% | ||
| Q1 25 | 7.3% | 9.4% | ||
| Q4 24 | 10.3% | 11.8% | ||
| Q3 24 | 10.0% | 10.2% | ||
| Q2 24 | 9.3% | 6.3% | ||
| Q1 24 | 7.6% | 5.6% |
| Q4 25 | 1.34× | 0.95× | ||
| Q3 25 | 2.15× | 1.66× | ||
| Q2 25 | 1.35× | 0.62× | ||
| Q1 25 | 2.18× | 1.43× | ||
| Q4 24 | 1.75× | 1.13× | ||
| Q3 24 | 2.24× | 1.22× | ||
| Q2 24 | 1.67× | 0.83× | ||
| Q1 24 | 1.68× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
SCI
| Cemetery | $510.9M | 46% |
| Funeral Matured Preneed Revenue | $196.5M | 18% |
| Cemetery Recognized Preneed Merchandise And Service Revenue | $107.4M | 10% |
| Cemetery Atneed Revenue | $104.9M | 9% |
| CA | $56.4M | 5% |
| Funeral Other Revenue | $54.6M | 5% |
| Cemetery Other Revenue | $40.2M | 4% |
| Nonfuneral Home Revenue | $28.1M | 3% |
| Non Funeral Home Preneed Sales Revenue | $22.0M | 2% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
